Home
>
National Drug Code (NDC)
>
Xalkori
Xalkori - 0069-8141-20 - (CRIZOTINIB)
Drug Information of Xalkori
| Product NDC: | 0069-8141 |
| Proprietary Name: | Xalkori |
| Non Proprietary Name: | CRIZOTINIB |
| Active Ingredient(s): | 200 mg/1 & nbsp; CRIZOTINIB |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Xalkori
| Product NDC: | 0069-8141 |
| Labeler Name: | Pfizer Laboratories Div Pfizer Inc |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA202570 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20110826 |
Package Information of Xalkori
| Package NDC: | 0069-8141-20 |
| Package Description: | 60 CAPSULE in 1 BOTTLE (0069-8141-20) |
NDC Information of Xalkori
| NDC Code | 0069-8141-20 |
| Proprietary Name | Xalkori |
| Package Description | 60 CAPSULE in 1 BOTTLE (0069-8141-20) |
| Product NDC | 0069-8141 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | CRIZOTINIB |
| Dosage Form Name | CAPSULE |
| Route Name | ORAL |
| Start Marketing Date | 20110826 |
| Marketing Category Name | NDA |
| Labeler Name | Pfizer Laboratories Div Pfizer Inc |
| Substance Name | CRIZOTINIB |
| Strength Number | 200 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Kinase Inhibitor [EPC],Cytochrome P450 3A4 Inhibitors [MoA],Receptor Tyrosine Kinase Inhibitors [MoA] |
